Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Exact Sciences (NASDAQ:EXAS) has filed a lawsuit in federal court alleging that Geneoscopy’s ColoSense product infringes upon a key patent for its colorectal cancer screening test Cologuard.
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...
In the latest quarter, 7 analysts provided ratings for Exact Sciences (NASDAQ:EXAS), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Carol K. Coburn is a professor emerita of religious studies and director of the CSJ Heritage Center at Avila University. She is also a consultant for the Buchanan Initiative for Peace and ...
November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq ... Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in ...
Further survived by other loving relatives and friends. Carol was born on October 2, 1935 in Pontiac, Michigan, to Irwin and Esther (nee Greenberg) Kampner. She graduated from Pontiac High School ...
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...
Professor Carol J. White taught in the Santa Clara University Philosophy Department from 1976 until her death in 2000. Her book, Time & Death: Heidegger's Analysis of Finitude was published ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...